[Variants of the course of non-alcoholic fatty liver disease in patients with ischemic heart disease and possibility of hypolipidemic therapy].

In developed countries cardiovascular pathology is the leading cause of death among the population in more than 50% cases. In 30% of patients the ischemic heart disease is related to obesity, which accompanies steatosis and steatohepatitis. Disturbance of lipid metabolism plays one of the key roles in combination of ischemic heart disease and non-alcoholic fatty liver disease. Possibilities of safe administration of hypolipidemic therapy in patients with disturbance of lipid metabolism have not been studied completely. The aim of the research was to evaluate variants of the course of non-alcoholic fatty liver disease in patients with ischemic heart disease and possibilities of safe hypolipidemic therapy. 60 patients with chronic heart disease in combination with non-alcoholic fatty liver disease have been examined. On investigation three variants of non-alcoholic fatty liver disease course in patients with ischemic heart disease have been differentiated on the basis of portal vein size, levels of liver transaminase and index of 13C-methaticine respiratory test. Important differences of steatohepatitis from steatosis are increased level of aspartate aminotransferase, lowered liver metabolism by 30% and decreased cumulative dose by 42%. Patients with ischemic heart disease and steatosis are recommended hypolipidemic therapy according to standards of treatment. At the same time hypolipidemic agents should be administered with caution to the patients with ischemic heart disease and steatohepatitis.